Scorpion venom may lead to improved arthritis treatment

A component of scorpion venom may help treat rheumatoid arthritis without causing side effects associated with existing treatments, a study has found.
The component can reduce the severity of the disease in animal models, researchers said.
"Rheumatoid arthritis is an autoimmune disease - one in which the immune system attacks its own body. In this case, it affects the joints," said Christine Beeton, associate professor at Baylor College of Medicine in the US.
"Cells called fibroblast-like synoviocytes (FLS) play a major role in the disease. As they grow and move from joint to joint, they secrete products that damage the joints and attract immune cells that cause inflammation and pain," Beeton said.

"As damage progresses, the joints become enlarged and are unable to move," she said.
Current treatments target the immune cells involved in the disease and none are specific for FLS. Researchers studied FLS in animal models looking for an 'Achilles' heel' that would allow them to prevent or stop them from damaging the joints.

"In previous work, we identified a potassium channel on FLS of patients with rheumatoid arthritis and found that the channel was very important for the development of the disease," Beeton said.
"We wanted to find a way to block the channel to stop the cells damaging the joints," she said.

Potassium channels work by opening gates on the surface of cells that allow potassium ions - small charged atoms - to flow in and out of the cell.
The flow of ions through the channels is necessary for the cells to carry out many of their essential functions. Animals such as scorpions have venoms that block potassium and other ion channels.
They use the venoms to paralyse and kill prey. Decades ago, scientists discovered this and realised that, if handled correctly, venoms also might have medicinal applications.
"Scorpion venom has hundreds of different components," said Mark Tanner, a graduate student in the Beeton lab.

"One of the components in the venom of the scorpion called Buthus tamulus specifically blocks the potassium channel of FLS and not the channels in other cells such as those of the nervous system," Tanner said.
"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease," he said.
When the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.
In some cases they reversed the signs of established disease, meaning that the animals had better joint mobility and less inflammation in their joints.

In addition, treatment with iberiotoxin did not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.
"It was very exciting to see that iberiotoxin is very specific for the potassium channel in FLS and that it did not seem to affect the channels in other types of cells, which might explain the lack of tremors and incontinence," Tanner said.
"Although these results are promising, much more research needs to be conducted before we can use scorpion venom components to treat rheumatoid arthritis," Beeton said.
"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future," he said.